Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:activeIngredient |
gptkb:busulfan
|
| gptkbp:approvedBy |
1950s
|
| gptkbp:ATCCode |
L01AB01
|
| gptkbp:chemicalClass |
antineoplastic agent
|
| gptkbp:contraindication |
pregnancy
hypersensitivity to busulfan |
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:eliminationHalfLife |
2.5 hours
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Myleran
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedIn |
gptkb:United_Kingdom
gptkb:United_States |
| gptkbp:mechanismOfAction |
DNA crosslinking
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
D
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting infertility pulmonary fibrosis bone marrow suppression |
| gptkbp:usedFor |
gptkb:chronic_myeloid_leukemia
bone marrow transplantation conditioning |
| gptkbp:bfsParent |
gptkb:busulfan
|
| gptkbp:bfsLayer |
7
|